3
Total investments
2
Early stage
0
Mid stage
1
Late stage
12y
Years active
Portfolio
3 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Angel Investor
Oct 2022
Embla is a turnkey, digital weight care solution built for cost-conscious U.S. employers.
We combine GLP-1 microdosing with expert psychology-based coaching to deliver 16.7% average weight loss in 12 months — using 55% less medication. That means better outcomes, fewer side effects, and lower costs.
We handle everything end-to-end: providers, prescriptions, pharmacy, PBM, and employee onboarding. No admin burden. No health plan integration. Fully live in 7 days with simple, pay-per-active-member pricing.
Founded in Denmark — the home of GLP-1 — Embla is trusted by U.S. health systems and self-funded employers. Our approach is validated by one of the largest real-world GLP-1 studies and supported by partnerships with the University of Copenhagen and biotech giant Novonesis.
Affordable GLP-1 coverage starts here.
Angel Investor
Apr 2022
ImagineCare offers a leading digital platform for Remote Patient Monitoring, RPM, where patients measure their values from home and have continuous and direct contact with their caregivers through an app.
Our platform is developed with input from healthcare professionals and is fully scalable for new demands. The ImagineCare solution is, therefore, a core for all remote monitoring, one that can grow towards new user areas and health flows continuously. Through this, ImagineCare is a tenable solution for both today’s and tomorrow’s healthcare needs.
You can read more about us and our platform at imaginecare.com.
Angel Investor
May 2014
#Nanolive: Capture dynamic, unbiased live cell data to accelerate discovery, development and therapeutics.
Nanolive delivers breakthrough 3D imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. Nanolive’s innovative solutions combine screening, imaging and analysis to radically advance how scientists study living cells and provide novel biological insights such as the mechanisms of cancer and neurodegenerative diseases.
Experience · 3 entries
All (3)
Investments (3)
2022
Angel Investor
Oct 2022
Embla is a turnkey, digital weight care solution built for cost-conscious U.S. employers.
We combine GLP-1 microdosing with expert psychology-based coaching to deliver 16.7% average weight loss in 12 months — using 55% less medication. That means better outcomes, fewer side effects, and lower costs.
We handle everything end-to-end: providers, prescriptions, pharmacy, PBM, and employee onboarding. No admin burden. No health plan integration. Fully live in 7 days with simple, pay-per-active-member pricing.
Founded in Denmark — the home of GLP-1 — Embla is trusted by U.S. health systems and self-funded employers. Our approach is validated by one of the largest real-world GLP-1 studies and supported by partnerships with the University of Copenhagen and biotech giant Novonesis.
Affordable GLP-1 coverage starts here.
Angel Investor
Apr 2022
ImagineCare offers a leading digital platform for Remote Patient Monitoring, RPM, where patients measure their values from home and have continuous and direct contact with their caregivers through an app.
Our platform is developed with input from healthcare professionals and is fully scalable for new demands. The ImagineCare solution is, therefore, a core for all remote monitoring, one that can grow towards new user areas and health flows continuously. Through this, ImagineCare is a tenable solution for both today’s and tomorrow’s healthcare needs.
You can read more about us and our platform at imaginecare.com.
2014
Angel Investor
May 2014
#Nanolive: Capture dynamic, unbiased live cell data to accelerate discovery, development and therapeutics.
Nanolive delivers breakthrough 3D imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. Nanolive’s innovative solutions combine screening, imaging and analysis to radically advance how scientists study living cells and provide novel biological insights such as the mechanisms of cancer and neurodegenerative diseases.
Investment activity
2014–2022 · 3 investments
Recent (last 2 years)Earlier
